The effects of LPM570065, a novel triple reuptake inhibitor, on extracellular serotonin, dopamine and norepinephrine levels in rats

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Zhang, Rats Renyu ^a,b   Li, Xiang ^a,b   Shi, Yanan ^a,b   Shao, Yufeng ^b   Sun, Kaoxiang ^b,c   Wang, Aiping ^b,c   Sun, Fengying ^a   Liu, Wanhui ^b,c   Wang, Di ^a   Jin, Jingji ^a   Li, Youxin ^a,b,c  

^a JILIN UNIVERSITY   (China)

^b State Key Laboratory of Long acting and Targeting Drug Delivery System   (China)

^c YANTAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (DIMETHYLAMINO) 1 (1 HYDROXYCYCLOHEXYL)ETHYL]PHENYL 4 METHYLBENZOATE HYDROCHLORIDE; DESVENLAFAXINE; DOPAMINE; LPM 570065; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; SEROTONIN; SEROTONIN 1A RECEPTOR; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; 4-(2-(DIMETHYLAMINO)-1-(1-HYDROXYCYCLOHEXYL)ETHYL)PHENYL 4-METHYLBENZOATE; ANTIDEPRESSANT AGENT; BENZOIC ACID DERIVATIVE; CYCLOHEXANOL DERIVATIVE; N-(2-(4-(2-METHOXYPHENYL)-1-PIPERAZINYL)ETHYL)-N-(2-PYRIDINYL)CYCLOHEXANECARBOXAMIDE; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FORCED SWIM TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; RAT; SEROTONINERGIC TRANSMISSION; ANIMAL; CHEMISTRY; DRUG EFFECTS; EXTRACELLULAR SPACE; METABOLISM; SPRAGUE DAWLEY RAT; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZOATES; CYCLOHEXANOLS; DESVENLAFAXINE SUCCINATE; DOPAMINE; EXTRACELLULAR SPACE; MALE; MICRODIALYSIS; NOREPINEPHRINE; PIPERAZINES; PYRIDINES; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SWIMMING;

EID: 84897499368     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091775     Document Type: Article

References (60)

1. Belmaker R, Agam G (2008) Major depressive disorder. New Engl J Med 358: 55-68.
2. Mann JJ (2005) The medical management of depression. New Engl J Med 353: 1819-1834.
3. Prins J, Olivier B, Korte SM (2011) Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. Expert Opin Inv Drug 20: 1107-1130.
4. Baldwin DS, Papakostas GI (2005) Symptoms of fatigue and sleepiness in major depressive disorder. J Clin Psychiat 67: 9-15.
5. Fava M, Graves LM, Benazzi F, Scalia MJ, Iosifescu DV, et al. (2006) A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J Clin Psychiat 67: 1754-1759. (Pubitemid 44955157)
6. Roy A, Karoum F, Pollack S (1992) Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiat 49: 447-450.
7. Klimek V, Schenck JE, Han H, Stockmeier CA, Ordway GA (2002) Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol Psychiat 52: 740-748.
8. Lam RW, Hossie H, Solomons K, Yatham LN (2004) Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiat 65: 337-340.
9. Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, et al. (2005) Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 66: 1289-1297. (Pubitemid 41546509)
10. Dunlop BW, Nemeroff CB (2007) The role of dopamine in the pathophysiology of depression. Arch Gen Psychiat 64: 327-337. (Pubitemid 46376789)
11. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, et al. (2006) Medication augmentation after the failure of SSRIs for depression. New Engl J Med 354: 1243-1252.
12. Fava M, Rankin M (2002) Sexual functioning and SSRIs. J Clin Psychiat 63: 13-16.
13. Breuer M, Chan J, Oosting R, Groenink L, Korte S, et al. (2008) The triple monoaminergic reuptake inhibitor DOV 216, 303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects. Eur Neuropsychopharm 18: 908-916.
14. Guiard BP, El Mansari M, Merali Z, Blier P (2008) Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electro-physiological study in rats with monoaminergic lesions. Int J Neuropsychoph 11: 625-639. (Pubitemid 351931823)
15. Millan MJ, Lejeune F, Gobert A (2000) Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychopharmacol 14: 114-138. (Pubitemid 30389486)
16. Guiard BP, Chenu F, Mansari ME, Blier P (2011) Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons. Int J Neuropsychoph 14: 211-223.
17. Tian JW, Jiang WL, Zhong Y, Meng Q, Gai Y, et al. (2011) Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties. Neuroscience 196: 124-130.
18. Spina E, Trifirò G, Caraci F (2012) Clinically significant drug interactions with newer antidepressants. CNS Drugs 26: 39-67.
19. Mart́in-Ruiz R, Ugedo L, Honrubia MA, Mengod G, Artigas F (2001) Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus. J Neurochem 77: 762-775. (Pubitemid 32466773)
20. Alexander GE, Crutcher MD (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 13: 266-271. (Pubitemid 20193456)
21. Alexander GE, Crutcher MD, DeLong MR (1991) Basal ganglia-thalamocor- tical circuits: parallel substrates for motor, oculomotor, " prefrontal" and "limbic" functions. Prog Brain Res 85: 119-146.
22. Amat J, Sparks P, Matus-Amat P, Griggs J, Watkins L, et al. (2001) The role of the habenular complex in the elevation of dorsal raphe nucleus serotonin and the changes in the behavioral responses produced by uncontrollable stress. Brain Res 917: 118-126. (Pubitemid 32972136)
23. Guilding C, Piggins HD (2007) Challenging the omnipotence of the suprachiasmatic timekeeper: are circadian oscillators present throughout the mammalian brain? Eur J Neurosci 25: 3195-3216. (Pubitemid 46872769)
24. Lecourtier L, Kelly PH (2007) A conductor hidden in the orchestra? Role of the habenular complex in monoamine transmission and cognition. Neurosci Biobehav R 31: 658-672. (Pubitemid 46680450)
25. Morissette MC, Boye SM (2008) Electrolytic lesions of the habenula attenuate brain stimulation reward. Behav Brain Res 187: 17-26. (Pubitemid 350216185)
26. Parent M, Lévesque M, Parent A (2001) Two types of projection neurons in the internal pallidum of primates: Single-axon tracing and three-dimensional reconstruction. J Comp Neurol 439: 162-175. (Pubitemid 32906020)
27. Geisler S, Trimble M (2008) The lateral habenula: no longer neglected. CNS Spectr 13: 484-489. (Pubitemid 351960773)
28. Li K, Zhou T, Liao L, Yang Z, Wong C, et al. (2013) bCaMKII in Lateral Habenula Mediates Core Symptoms of Depression. Science 341: 1016-1020.
29. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, et al. (2006) Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318: 657-665. (Pubitemid 44061240)
30. Alfinito PD, Huselton C, Chen X, Deecher DC (2006) Pharmacokinetic and pharmacodynamic profiles of the novel serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized Sprague-Dawley rats. Brain Res 1098: 71-78. (Pubitemid 44277990)
31. Paxinos G, Watson C (2007) The rat brain in stereotaxic coordinates. sixth ed. Manhattan: Academic Press.
32. Yoshitake T, Fujino K, Kehr J, Ishida J, Nohta H, et al. (2003) Simultaneous determination of norepinephrine, serotonin, and 5-hydroxyindole-3-acetic acid in microdialysis samples from rat brain by microbore column liquid chromatography with fluorescence detection following derivatization with benzylamine. Anal Biochem 312: 125-133. (Pubitemid 36151122)
33. Yoshitake T, Kehr J, Yoshitake S, Fujino K, Nohta H, et al. (2004) Determination of serotonin, noradrenaline, dopamine and their metabolites in rat brain extracts and microdialysis samples by column liquid chromatography with fluorescence detection following derivatization with benzylamine and 1, 2-diphenylethylenediamine. J Chromatogr B 807: 177-183. (Pubitemid 38759981)
34. Zhang Y, Zhu X, Bai M, Zhang L, Xue L, et al. (2013) Maternal Deprivation Enhances Behavioral Vulnerability to Stress Associated with miR-504 Expression in Nucleus Accumbens of Rats. PLOS ONE 8: e69934.
35. Barr JL, Forster GL (2011) Serotonergic neurotransmission in the ventral hippocampus is enhanced by corticosterone and altered by chronic amphetamine treatment. Neuroscience 182: 105-114.
36. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, et al. (2011) Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Brit J Pharmacol 164: 1949-1958.
37. Beyer CE, Boikess S, Luo B, Dawson LA (2002) Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol 16: 297-304. (Pubitemid 35470573)
38. 1A receptor antagonist DU-125530 for antidepressant treatment. Brit J Pharmacol 167: 1021-1034.
39. 1A receptors in rats treated chronically with a novel antidepressant, cericlamine. J Pharmacol Exp Ther 268: 1432-1443. (Pubitemid 24100364)
40. Kreiss DS, Lucki I (1995) Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 274: 866-876.
41. 1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 39: 110-122.
42. Liederer BM, Borchardt RT (2006) Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 95: 1177-1195. (Pubitemid 43874435)
43. Cryan JF, Markou A, Lucki I (2002) Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245. (Pubitemid 34465544)
44. Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, et al. (2006) Preclinical and clinical pharmacology of DOV 216, 303, a "triple" reuptake inhibitor. CNS Drug Rev 12: 123-134. (Pubitemid 44300380)
45. Yamada J, Sugimoto Y, Yamada S (2004) Involvement of dopamine receptors in the anti-immobility effects of dopamine re-uptake inhibitors in the forced swimming test. Eur J Pharmacol 504: 207-211. (Pubitemid 39488216)
46. Lavretsky H, Kumar A (2001) Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geriat Psychiat 9: 298-303. (Pubitemid 32642982)
47. Lavretsky H, Kim MD, Kumar A, Reynolds 3rd C (2003) Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J Clin Psychiat 64: 1410-1414. (Pubitemid 41270097)
48. Gorwood P (2008) Neurobiological mechanisms of anhedonia. Dialogues Clin Neurosci 10: 291-299.
49. Dawson L, Nguyen H, Smith D, Schechter L (2002) Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex. J Psychopharmacol 16: 145-152. (Pubitemid 34614884)
50. 1A receptors. Brit J Pharmacol 142: 469-478. (Pubitemid 38869860)
51. 2-like dopamine receptors depolarize dorsal raphe serotonin neurons through the activation of nonselective cationic conductance. J Pharmacol Exp Ther 320: 376-385. (Pubitemid 46025752)
52. 2-like dopamine receptor activation excites rat dorsal raphe 5-HT neurons in vitro. Eur J Neurosci 14: 125-134. (Pubitemid 32738481)
53. 2 receptors in apomorphine-induced facilitation of forebrain serotonin output. Eur J Pharmacol 351: 291-298. (Pubitemid 28321464)
54. 1A receptors. J Psychopharmacol 21: 795-804. (Pubitemid 350029186)
55. Golembiowska K, Kowalska M, Bymaster FP (2012) Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity. Synapse 66: 435-444.
56. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS (2003) Antidepressant-like actions of DOV 21, 947: a "triple" reuptake inhibitor. Eur J Pharmacol 461: 99-104. (Pubitemid 36174028)
57. Tizzano JP, Stribling DS, Perez-Tilve D, Strack A, Frassetto A, et al. (2008) The triple uptake inhibitor (1R, 5S)-(+)-1-(3, 4-dichlorophenyl)-3- azabicyclo [3.1. 0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity. J Pharmacol Exp Ther 324: 1111-1126. (Pubitemid 351397857)
58. Tran P, Skolnick P, Czobor P, Huang N, Bradshaw M, et al. (2012) Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiat Res 46: 64-71.
59. Hasler G, Drevets WC, Manji HK, Charney DS (2004) Discovering endophenotypes for major depression. Neuropsychopharmacol 29: 1765-1781. (Pubitemid 39336788)
60. Millan MJ (2009) Dual-and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 6: 53-77.